Jul 29, 2021 / 10:30AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q1 FY '22 Earnings Conference Call of Eris Lifesciences. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.
Krishnakumar Vaidyanathan - Eris Lifesciences Limited - Executive Director & COO
Thank you. Good afternoon, and welcome to our first quarter conference call. I'm Krishnakumar, and I'm happy to share the highlights of this quarter with you. As per AIOCD, the Indian pharma market growth for the quarter was 34% excluding COVID molecules. This growth was led by acute therapies, which have grown at 54% overall and at 44% -- 47% excluding COVID molecules largely on account of the low base of acute in quarter 1 of last year.
I'm happy to share that Eris continues to rank among the top 10 fastest-growing companies based on June MAT data. In fact, Eris is the only company on this list to have a single-digit contribution
Q1 2022 Eris Lifesciences Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot